A Comprehensive Analysis of How Chronological Age Affects Mesenchymal Stromal Cells' Ability to Chondrogenesis

Tillerson Harkonen^*
*Correspondence: Tillerson Harkonen, Department of Clinical Medicine, University of Cambridge, Cambridge CB2 2SP, UK, Email:

Keywords

Mesenchymal stromal cells • Chondrogenesis • Chronological age • Cartilage repair • Regenerative medicine

Introduction

Mesenchymal stromal cells (MSCs) have emerged as a promising tool in regenerative medicine due to their ability to differentiate into various cell types, including chondrocytes and contribute to tissue repair and regeneration. However, the effectiveness of MSC-based therapies for cartilage repair may be influenced by the donor's chronological age. Understanding how chronological age affects the chondrogenic potential of MSCs is essential for optimizing therapeutic outcomes and addressing age-related challenges in cartilage regeneration. This article aims to provide a comprehensive analysis of the relationship between chronological age and MSCs' ability to undergo chondrogenesis, exploring the underlying mechanisms and potential strategies to enhance chondrogenic potential. Studies have shown that MSCs derived from older donors exhibit decreased proliferative capacity compared to those from younger donors. This reduced proliferation may limit the availability of MSCs for chondrogenic differentiation, impacting the efficiency of cartilage repair processes.

Age-related changes in MSCs' differentiation potential have been reported, with some studies suggesting a decline in chondrogenic differentiation capacity with increasing chronological age. This decline may be attributed to alterations in signaling pathways, epigenetic modifications and changes in the cellular microenvironment. Chronological age has been shown to influence the gene expression profiles of MSCs, with alterations in the expression of genes associated with chondrogenesis, extracellular matrix synthesis and inflammatory pathways. Deregulated gene expression may impair MSCs' ability to undergo chondrogenic differentiation and contribute to cartilage repair processes. Age-related changes in the composition and properties of the Extracellular Matrix (ECM) can impact MSCs' chondrogenic potential. Alterations in ECM stiffness, composition, and organization may affect cell-matrix interactions, signaling cascades, and ultimately, the efficiency of chondrogenic differentiation [1].

Literature Review

Preconditioning MSCs through exposure to biochemical or mechanical stimuli, such as hypoxia, cytokines, or mechanical loading, can prime cells for enhanced chondrogenic differentiation. Preconditioning strategies aim to modulate cellular responses, promote stemness and improve the regenerative potential of aging MSCs for cartilage repair applications. Chronological age exerts a significant influence on the chondrogenic potential of MSCs, impacting their proliferation capacity, differentiation potential, gene expression profiles, and interaction with the extracellular matrix. Understanding the age-related dynamics of MSCs in chondrogenesis is crucial for optimizing regenerative therapies and addressing challenges associated with cartilage repair in aging populations. Strategies to enhance chondrogenic potential in aging MSCs, such as optimization of culture conditions, genetic and epigenetic modification, combination therapies, and preconditioning strategies, hold promise for improving therapeutic outcomes and advancing the field of regenerative medicine in cartilage repair. Continued research efforts aimed at unraveling the underlying mechanisms of age-related changes in MSCs and developing innovative strategies to overcome age-related limitations are essential for realizing the full therapeutic potential of MSC-based therapies in cartilage regeneration [2].

Translating findings from preclinical studies to clinical applications requires careful consideration of patient-specific factors, such as age-related comorbidities, disease severity and treatment history. Clinical trials evaluating MSC-based therapies for cartilage repair in aging populations should incorporate age-stratified analyses to assess the impact of chronological age on treatment outcomes. Moreover, personalized treatment approaches, tailored to individual patient characteristics and biological age, may optimize therapeutic efficacy and long-term success. Integrating patient-specific factors into treatment algorithms and optimizing regenerative strategies based on age-related considerations can enhance clinical outcomes and facilitate the widespread adoption of MSC-based therapies for cartilage repair in aging populations [3].

Mesenchymal Stromal Cells (MSCs) hold great promise for cartilage repair and regeneration in aging populations, but the impact of chronological age on MSC-based therapies remains a topic of significant interest and investigation. Addressing age-related changes in MSCs' chondrogenic potential requires a multifaceted approach encompassing basic science research, translational studies, clinical trials and personalized treatment strategies. By elucidating the underlying mechanisms of age-related changes in MSCs, optimizing regenerative protocols and integrating patient-specific considerations into treatment algorithms, clinicians and researchers can harness the full therapeutic potential of MSC-based therapies for cartilage repair in aging populations. Ethical, regulatory and safety considerations must also be carefully managed to ensure the responsible translation of MSC-based therapies from bench to bedside. Continued collaboration, innovation and evidence-based practice are essential for advancing the field of regenerative medicine and improving outcomes for patients with age-related cartilage defects [4].

Discussion

Understanding the economic implications of MSC-based therapies for cartilage repair in aging populations is essential for healthcare decision-makers, policymakers, and stakeholders. While regenerative therapies hold promise for improving patient outcomes and reducing the economic burden of chronic joint diseases, cost-effectiveness analyses are needed to evaluate the long-term value of these interventions. Factors such as treatment costs, resource utilization, healthcare utilization and productivity gains should be considered in economic evaluations to inform healthcare resource allocation and reimbursement decisions. Furthermore, healthcare policies and reimbursement frameworks should be aligned with evidence-based practice and patient-centered care to ensure equitable access to regenerative therapies for all eligible patients, regardless of age or socioeconomic status.

MSC-based therapies for cartilage repair should be integrated into multimodal treatment approaches that address the multifactorial nature of joint degeneration in aging populations. Combining regenerative therapies with conventional treatments, such as physical therapy, pharmacotherapy, orthopedic interventions and lifestyle modifications, can synergistically enhance treatment outcomes and improve long-term joint health. Tailoring treatment strategies to individual patient needs, preferences, and disease severity allows for personalized care and optimized outcomes. Multidisciplinary collaboration among healthcare professionals, including orthopedic surgeons, rheumatologists, physiatrists and rehabilitation specialists, is essential for developing comprehensive treatment plans and coordinating care for patients with age-related cartilage defects [5].

Educating healthcare professionals, patients, and the public about the potential benefits and limitations of MSC-based therapies for cartilage repair in aging populations is crucial for informed decision-making and shared decision-making. Providing accurate information about treatment options, evidence-based recommendations and realistic expectations fosters patient engagement, empowers shared decision-making, and promotes patient-centered care. Public awareness campaigns, educational resources, and community outreach initiatives play a vital role in dispelling myths, addressing misconceptions and promoting understanding of regenerative medicine approaches in joint health and aging. By enhancing health literacy and promoting informed decision-making, education initiatives empower patients to actively participate in their care and advocate for access to evidence-based treatments [6].

Conclusion

Promoting global collaboration and knowledge sharing in the field of regenerative medicine fosters innovation, accelerates scientific discovery, and expands access to advanced therapies for cartilage repair in aging populations. Collaborative research networks, consortia, and international partnerships facilitate the exchange of expertise, resources, and best practices across borders, driving progress in regenerative medicine research and clinical translation. Open access to scientific literature, data sharing initiatives, and collaborative research platforms promote transparency, reproducibility, and dissemination of research findings, enabling researchers and clinicians worldwide to build upon existing knowledge and contribute to advancements in the field. By fostering a culture of collaboration and knowledge sharing, the global community can collectively address the challenges of age-related cartilage defects and improve patient outcomes through regenerative medicine approaches.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Ding, Dah-Ching, Yu-Hsun Chang, Woei-Cherng Shyu and Shinn-Zong Lin. "Human umbilical cord mesenchymal stem cells: A new era for stem cell therapy." Cell Transplant 24 (2015): 339-347.

Google Scholar, Crossref, Indexed at

2. Yao, Panpan, Liping Zhou, Lujie Zhu and Binjie Zhou, et al. "Mesenchymal stem cells: A potential therapeutic strategy for neurodegenerative diseases." Eur Neurol 83 (2020): 235-241.

Google Scholar, Crossref, Indexed at

3. Hernandez, Rosa, Cristina Jiménez-Luna, Jesús Perales-Adán and Gloria Perazzoli, et al. "Differentiation of human mesenchymal stem cells towards neuronal lineage: Clinical trials in nervous system disorders." Biomol Ther 28 (2020): 34.

Google Scholar, Crossref, Indexed at

4. Huang, GT-J., S. Gronthos and S. Shi. "Critical reviews in oral biology & medicine: Mesenchymal stem cells derived from dental tissues vs. those from other sources: Their biology and role in regenerative medicine." J Dent Res 88 (2009): 792.

Google Scholar, Crossref, Indexed at

5. Metcalf, Donald. "Concise review: Hematopoietic stem cells and tissue stem cells: Current concepts and unanswered questions." Stem Cells 25 (2007): 2390-2395.

Google Scholar, Crossref, Indexed at

6. Choi, Moran, Hyun-Sun Lee, Purevjargal Naidansaren and Hyun-Kyung Kim, et al. "Proangiogenic features of Wharton's jelly-derived mesenchymal stromal/stem cells and their ability to form functional vessels." Int J Biochem Cell Biol 45 (2013): 560-570.

Google Scholar, Crossref, Indexed at